Jco precision oncology.

DOI: 10.1200/PO.18.00325 JCO Precision Oncology - published online June 13, 2019By choosing this option you are agreeing to pay the article processing charge of $2,300 (Original Reports) or $792 (Case Reports). This will be billed after acceptance of your …The Precision Oncology Decision Support system (PODS) was established at The University of Texas MD Anderson Cancer Center in recognition of these needs. 9 Herein, we report our experience with large-scale, institution-wide decision support and its initial clinical utility. These data are among the first to suggest that providing alteration ...Soft boiled eggs are a delicious and versatile dish that can be enjoyed for breakfast, lunch, or dinner. Cooking the perfect soft boiled egg requires precision and attention to detail.By choosing this option you are agreeing to pay the article processing charge of $2,300 (Original Reports) or $792 (Case Reports). This will be billed after acceptance of your article. Open access requirements may vary depending on the source of funding for your submission. If you have questions regarding open access requirements, this guide to ...

DOI: 10.1200/PO.18.00414 JCO Precision Oncology no. 4 (2020) 557-569. Published online June 1, 2020. PMID: 32923885. Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients Jingyu Cao, MD 1. x. Jingyu Cao. Search for articles by this author; Jing ...PURPOSE Precision medicine uses advanced molecular techniques to guide the use of targeted therapeutic drugs and is an emerging paradigm in pediatric oncology. Clinical evidence related to the efficacy of many novel targeted drugs, however, is currently very limited given the rarity of pediatric cancer and the lack of published evidence for the …

Oct 3, 2017 · DOI: 10.1200/PO.17.00073 JCO Precision Oncology - published online October 3, 2017

DOI: 10.1200/PO.23.00176 JCO Precision Oncology no. 7 (2023) e2300176. Published online December 1, 2023. PMID: 38039430. Utility of Tumor Mutational Burden as a …DOI: 10.1200/PO.19.00253 JCO Precision Oncology no. 4 (2020) 66-73. Published online February 13, 2020. PMID: 35050730. Utility of Circulating Tumor DNA in the Management of Patients With GI Stromal Tumor: Analysis of 243 Patients Junaid Arshad, MD 1. x. Junaid Arshad. Search for articles by this author ...DOI: 10.1200/PO.22.00604 JCO Precision Oncology no. 7 (2023) e2200604. Published online July 12, 2023. PMID: 37437231. Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies Akram Mesleh Shayeb, MD 1. x. Akram Mesleh Shayeb. Search for articles …This author is an Associate Editor for JCO Precision Oncology. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: Ciitizen Corporation, Clariifi, Guidance Genomics. Consulting or Advisory Role: Roche, Roche/Genentech. Speakers' Bureau: Genentech

Precision oncology strategies are an important and growing component of cancer care. There are over 90 US Food and Drug Administration–approved targeted therapies available for use in eligible patients with cancer, 1 and a recent oncology pipeline report showed that approximately 55% of all oncology clinical trials involved the use of biomarkers. 2 Predictive biomarker testing to help ...

Lung cancer is the leading cause of cancer-related death worldwide. Non–small-cell lung cancer (NSCLC), which accounts for 85% of all lung cancer cases, 1 is a group of heterogeneous diseases driven by a spectrum of molecular alterations. Targeted therapies directed toward specific molecular alterations, such as a mutation in epidermal …

DOI: 10.1200/PO.23.00044 JCO Precision Oncology no. 7 (2023) e2300044. Published online June 29, 2023. PMID: 37384864. 31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration Christine N. Bailey, MPH 1. x. Christine N. Bailey. Search for articles …WebPURPOSE Whether germline multigene panel testing (MGPT) should be performed in all individuals with colorectal cancer (CRC) remains uncertain. Therefore, we aimed to determine the yield and potential clinical impact of MGPT across a large, diverse CRC cohort. METHODS This was a retrospective cohort study of adults with CRC who underwent MGPT of > 10 genes at a commercial laboratory between ...In this prospective, case-control study, we assessed the performance of a blood-based multi-cancer detection test to detect cancer and predict the origin of the cancer signal in individuals with symptoms suspicious for cancer.Oct 3, 2017 · DOI: 10.1200/PO.17.00073 JCO Precision Oncology - published online October 3, 2017 DOI: 10.1200/PO.20.00250 JCO Precision Oncology no. 5 (2021) 204-214. Published online January 14, 2021. Published online January 14, 2021. NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome

The actual frequency of NTRK fusions in thyroid cancer is not known, as some targeted exome sequencing can easily miss fusion event involving introns of certain genes. Studies on frequency of NTRK fusions from a single institution and from the TCGA found NTRK fusion in 10 of 451 (2.2%; four NTRK1 and six NTRK3 fusions) and 12 of 498 (2.4%; five ...DOI: 10.1200/PO.19.00124 JCO Precision Oncology - published online August 14, 201915 Sept 2023 ... 5. Johnson A , Khotskaya YB , Brusco L , et al. Clinical use of precision oncology decision support. JCO Precis Oncol. 2017. doi:10.1200 ...DOI: 10.1200/PO.19.00116 JCO Precision Oncology - published online August 29, 2019WebThe increased affordability, accessibility, and reliability of DNA and RNA high-throughput sequencing platforms and bioinformatics capabilities enable oncologists to provide more personalized care, often referred to as precision oncology. 1 However, the accelerated development and diffusion of new commercial and noncommercial tumor …Supported by The Cholangiocarcinoma Foundation (to M.Y.), the National Cancer Institute Specialized Program of Research Excellence (SPORE) in Gastrointestinal Cancers (P50 CA062924), the NIH Center Core Grant (P30 CA006973), and the American Society of Clinical Oncology Career Development Award.

As such, scientific outlets in general, and JCO Precision Oncology in particular, owe an immense debt of gratitude to our volunteer peer reviewers. JCO PO strives to provide the highest quality peer review, so in recognition of Peer Review Week 2023 and its theme of Peer Review and The Future of Publishing, ...

Precision oncology relies on robust molecular analyses of patient samples and accurate interpretation of genomic sequencing and biomarker data. 1 Advances in genomic sequencing have made tumor genomic profiling a routine process in the clinical evaluation and treatment planning of patients with cancer. 2 The main objective is to provide a detailed characterization of a patient's neoplasm ...Mar 9, 2022 · PURPOSE Earlier detection of cancer recurrence using circulating tumor DNA (ctDNA) to detect molecular residual disease (MRD) has the potential to dramatically affect cancer management. We review evidence supporting the use of ctDNA as a biomarker for detection of MRD and highlight the potential impact that ctDNA testing could have on the conduct of clinical trials. METHODS We searched the ... DOI: 10.1200/PO.20.00534 JCO Precision Oncology no. 5 (2021) 771-778. Published online May 3, 2021. Published online May 3, 2021. Clinical Responses to Crizotinib, Alectinib, and Lorlatinib in a Metastatic Colorectal Carcinoma Patient With ALK Gene Rearrangement: A Case ReportDOI: 10.1200/PO.20.00241 JCO Precision Oncology no. 5 (2021) 93-102. Published online January 11, 2021. PMID: 34994593. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non–Small-Cell Lung Cancer ...Oct 3, 2017 · DOI: 10.1200/PO.17.00073 JCO Precision Oncology - published online October 3, 2017 DOI: 10.1200/PO.23.00176 JCO Precision Oncology no. 7 (2023) e2300176. Published online December 1, 2023. PMID: 38039430. Utility of Tumor Mutational Burden as a …Purpose With prospective clinical sequencing of tumors emerging as a mainstay in cancer care, an urgent need exists for a clinical support tool that distills the clinical implications associated with specific mutation events into a standardized and easily interpretable format. To this end, we developed OncoKB, an expert-guided precision …

DOI: 10.1200/PO.18.00401 JCO Precision Oncology - published online June 20, 2019 Plasma Cell-Free DNA Testing of Patients With EGFR Mutant Non–Small-Cell Lung Cancer: Droplet Digital PCR Versus Next-Generation Sequencing Compared With Tissue-Based Results

Supported by The Cholangiocarcinoma Foundation (to M.Y.), the National Cancer Institute Specialized Program of Research Excellence (SPORE) in Gastrointestinal Cancers (P50 CA062924), the NIH Center Core Grant (P30 CA006973), and the American Society of Clinical Oncology Career Development Award.

OncoKB, a comprehensive and curated precision oncology knowledge base, offers oncologists detailed, evidence-based information about individual somatic …PURPOSE The adoption of precision medicine (PMed) depends on the critical curation of data and interpretation of genomic results. Herein, we sought to study the effect of a coordinated multidisciplinary program to assess results in a community cancer center clinic. METHODS In a retrospective review from July 2018 to July 2021, we …DOI: 10.1200/PO.19.00116 JCO Precision Oncology - published online August 29, 2019WebDOI: 10.1200/PO.20.00534 JCO Precision Oncology no. 5 (2021) 771-778. Published online May 3, 2021. Published online May 3, 2021. Clinical Responses to Crizotinib, Alectinib, and Lorlatinib in a Metastatic Colorectal Carcinoma Patient With ALK Gene Rearrangement: A Case ReportDOI: 10.1200/PO.17.00075 JCO Precision Oncology - published online October 10, 2017The American Society of Clinical Oncology explains that the end stage of cancer is diagnosed when the cancer has spread to other parts of the body. This stage is also called stage 4, advanced or metastatic cancer.DOI: 10.1200/PO.20.00187 JCO Precision Oncology no. 4 (2020) 1163-1166. Published online September 29, 2020. PMID: 35050775. Targeted Therapy in BRAF p.K601E–Driven NSCLC: Case Report and Literature Review Felix C. Saalfeld, MD 1, 2. x. Felix C. Saalfeld. Search for articles by this author ...DOI: 10.1200/PO.21.00101 JCO Precision Oncology no. 5 (2021) 1166-1177. Published online July 21, 2021. Published online July 21, 2021. Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of MetastasesPURPOSE T-cell–mediated cytotoxicity is suppressed when programmed cell death-1 (PD-1) is bound by PD-1 ligand-1 (PD-L1) or PD-L2. Although PD-1 inhibitors have been approved for triple-negative breast cancer, the lower response rates of 25%-30% in estrogen receptor–positive (ER+) breast cancer will require markers to identify likely responders. The focus of this study was to evaluate ...

31 Aug 2022 ... Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): an MD Anderson Precision Medicine Study. JCO Precis. Oncol. 2017;2017.The increased affordability, accessibility, and reliability of DNA and RNA high-throughput sequencing platforms and bioinformatics capabilities enable oncologists to provide more personalized care, often referred to as precision oncology. 1 However, the accelerated development and diffusion of new commercial and noncommercial tumor …DOI: 10.1200/PO.18.00114 JCO Precision Oncology - published online February 6, 2019WebDOI: 10.1200/PO.21.00383 JCO Precision Oncology no. 6 (2022) e2100383. Published online February 21, 2022. Published online February 21, 2022. Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA SubstudyWebInstagram:https://instagram. google stock graphdulingo stockhow do you buy preferred stockqyld expense ratio 20 Oct 2022 ... JCO Precision Oncology. Source Reference: opens in a new tab or windowHubbeling H, et al "Outcomes with local therapy and tyrosine kinase ...DOI: 10.1200/PO.19.00115 JCO Precision Oncology - published online October 23, 2019 nyse dwhat is leverage in forex 28 Mar 2023 ... Dr Matteo Lambertini speaks to ecancer about the present and future of precision oncology in breast cancer. He begins by highlighting the ... fannie mae home loans for disabled DOI: 10.1200/PO.18.00383 JCO Precision Oncology - published online August 16, 2019 Tissue/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D–CDK4/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket Study Julio Peguero, MD 1. x. Julio Peguero. Search for articles by this author ...DOI: 10.1200/PO.18.00114 JCO Precision Oncology - published online February 6, 2019Web